Substance Use Scientific Working Group

Substance use is a well-established risk factor for HIV transmission. Furthermore, for people living with HIV, substance use and addiction can hasten HIV progression and its consequences. Despite its significant impact on HIV, the intersection of substance use and HIV prevention and treatment has been an underdeveloped research area.

We established the SU-SWG to fill this gap in research. The SU-SWG consists of Texas D-CFAR and affiliate members, including basic science, clinical, public health and health services researchers, with the expertise needed to address a wide range of areas relevant to research in the overlapping epidemics of substance use and HIV.

Substance Use Scientific Working Group  Services

• Information about ongoing research and external funding research opportunities on the intersection of substance use and HIV
• Pilot grant funding opportunities through the Developmental Core
• Monthly meetings to identify areas of research for the intersection between HIV and substance use
• Invited speakers with expertise in HIV and substance use
• Annual Texas D-CFAR Conference sessions dedicated to HIV and substance use

NIDA FALL/WINTER

RFA-DA-25-022 (R01) Advancing Technologies to Improve Delivery of Pharmacological, Gene Editing, and other Cargoes for HIV and SUD Mechanistic or Therapeutic Research (R01 Clinical Trial Optional)
RFA-DA-25-021 (R01) Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional)
RFA-DA-25-009 (R01) Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R01 Clinical Trial Not Allowed)
RFA-DA-25-010 (R21) Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R21 Clinical Trial Not Allowed)
RFA-DA-25-005 (R21) Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)
RFA-DA-25-004 (R01) Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Trial Not Allowed)
RFA-DA-24-037 (R21) Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)
RFA-DA-22-037 (R01) Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)
RFA-MH-25-180 (R01) Mechanisms of Reciprocal Interactions between HIV Associated Neuroinflammation and CNS Persistence: Implications in HIV Neuropathogenesis and Cure (R01 Clinical Trial Not Allowed)
RFA-MH-25-181 (R21) Mechanisms of Reciprocal Interactions between HIV Associated Neuroinflammation and CNS Persistence: Implications in HIV Neuropathogenesis and Cure (R21 Clinical Trial Not Allowed)
RFA-NS-24-035 (R61/R33) Novel Preclinical Models of NeuroHIV in the cART Era (R61/R33 - Clinical Trial Not Allowed)
RFA-DA-25-024 (R01) High Priority HIV and Substance Use Research (R01 Clinical Trial Optional) 
RFA-DA-25-060 (RM1) High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional) 
 

Office of AIDS Research Priority Areas

NOT-OD-24-119 Notice of Special Interest (NOSI): Research Opportunities Centering the Health of Women Across the HIV Research Continuum
PAR-24-092 Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional) 
PAR-24-091 Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)

NIDA SPRING

RFA-DA-26-001 (R01) Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R01 Clinical Trial Not Allowed)
RFA-DA-26-002 (R21) Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R21 Clinical Trial Not Allowed)
RFA-DA-26-007 (R01) Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R01 Clinical Trials Not Allowed)
RFA-DA-26-008 (R21) Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R21 Clinical Trials Not Allowed)
RFA-DA-25-012 (R01) Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
RFA-DA-25-013 (R21) Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)
 

View all NIDA funding opportunities at the intersection of HIV and substance use.